GTCBio is proud to introduce our 7th Annual Cancer Drugs Research and Development conference, scheduled to be held in San Diego, CA on January 28-29, 2010. Last year’s conference was a great success as leaders in oncology R&D from GlaxoSmithKline, AstraZeneca, Pfizer, Novartis, Abbott, Millenium, Wyeth, and others, gathered to discuss novel developments and important achievements in the field. We covered a range of topics from new drug compounds for cancer prevention to new delivery methods of targeted therapeutics.

This year, we will analyze case studies of the successes and challenges of modern Cancer Drugs and provide you with an update on Cancer Drugs currently in development through clinical trials. A look at novel compounds and emerging targets will prime you with an accurate future outlook on cancer drugs. Key topics to be discussed by leading experts including the use of biomarkers, mTOR inhibitors, angiogenesis, PARP inhibitors, PI3K inhibitors, RNAi targets, VEGF Receptor inhibitors, and much more. The new frontier of combination therapeutics and therapies will be also covered in detail.

The sessions will cover the following:

Session I: Targeting Session II: Monoclonal Antibodies Session III: Challenges of Modern Cancer Drugs Session IV: Novel Approaches and Emerging Targets Session V: Cancer Drugs in Clinical Trials

Learn, brainstorm and collaborate with your colleagues by signing up today!

We look forward to seeing you in San Diego.